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Background: Many medicines used in new-
borns, infants, children and adolescents are not li-
censed (“unlicensed”) or are prescribed outside the
terms of the marketing authorization (“off-label”).
Several studies have shown that this is a common
practice in various healthcare settings in the USA,
Europe and Australia, but data are scarce in
Switzerland.
Objectives: The aim of our prospective study
was to determine the proportion of unlicensed or
off-label prescriptions in paediatric patients.
Methods: This pilot study was conducted
prospectively over a six month period in the de-
partment of paediatrics of a university hospital.
Results: Sixty patients aged from three days to
14 years were included in the study. A total of 483
prescriptions were written for the patients. More
than half of all prescriptions (247; 51%) followed
the terms of the marketing authorization. 114
(24%) were unlicensed and 122 (25%) off-label.
All patients received at least one unlicensed or off-
label medicine.
Conclusion: The use of unlicensed or off-label
medicines to treat children was found to be com-
mon. Co-operation between the pharmaceutical
industry, national regulatory authorities, clinical
researchers, healthcare professionals and parents 
is required in order to ensure that children do not
remain “therapeutic orphans”.
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The licensing process of medicines aims at en-
suring their safety, effectiveness and high quality.
Most medicines used in adults fulfil these criteria.
In contrast, a serious dilemma in paediatric drug
labelling was identified more than thirty-five years
ago, the so-called “therapeutic orphans” [1, 2]. As
a matter of fact, many medicines used to treat chil-
dren are either not licensed (frequently referred to
as “unlicensed”) or are prescribed outside the
terms of their product license (“off-label”). A com-
mon case of unlicensed use in our country is the
preparation of a hydrochlorothiazide suspension
from tablets, since this suspension is not available
on the market. Examples of off-label use include
salbutamol metered-dose inhaler under 4 years
(off-label for age), or midazolam intravenous solu-
tion administered by nasal route for acute seizure
(off-label for indication and route of administra-
tion).
So far, several prospective and retrospective
studies have been conducted in various healthcare
contexts (general medical and surgical wards,
neonatal and paediatric intensive care units) in the
USA, Europe and Australia [3–10]. These studies
have brought to light a high proportion of unli-
censed and off-label use, reaching up to 72% of all
prescriptions and 93% of all paediatric patients.
Furthermore, an English study has shown that ad-
verse drug reactions in hospitalised children were
more frequently associated with unlicensed and
off-label drug prescriptions than with the licensed
ones (6% vs. 3.9%) [5].
Few comparable data are available in our
country, with only one preliminary report of a
study carried out in the neonatal and paediatric in-
tensive care units of the Basel University Hospital
[10]. Our study was therefore designed to assess
the extent and nature of unlicensed and off-label
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This pilot study was prospectively conducted over a
6-month period (from October 2001 to March 2002) at
the University Hospital CHUV and the Children’s Hos-
pital of Lausanne (HEL) (total: 100 beds). The proto-
col was accepted by the local Ethics Committee of the
Faculty of Biology and Medicine of the University of
Lausanne.
Data were collected from physicians’ drug prescrip-
tion sheets during 24 hours of hospitalisation for 60 ran-
domly chosen paediatric inpatients in six different wards:
50 patients from the CHUV (neonatal, paediatric inten-
sive care, intermediate care, medical, and surgical wards),
and 10 patients from the HEL ward. The details recorded
included the patient’s initials, date of prescription, ward,
date of birth, weight, diagnosis, and medicines (with
dosage form, dose and frequency of administration, route
of administration and special instructions). The patients’
age was classified according to the International Confer-
ence on Harmonisation [11]: a) preterm and term new-
born infants (0 to 27 days); b) infants and toddlers (28 days
to 23 months); c) children (2 to 11 years); and d) adoles-
cents (12 to 18 years). Standard intravenous replacement
solutions, sodium chloride 0.9% infusions, blood products
(except albumin) and oxygen were not recorded. For the
different wards, the indication for use of the drugs was dis-
cussed with the responsible physician.
All prescriptions were similarly analysed to determine
whether the medicines were used in a licensed or un-
licensed manner. Unlicensed medicines were subdivided
into three classes: 1) medicines prepared or modified by
the hospital pharmacy (batch or extemporaneous prepa-
rations); 2) medicines prepared by authorized manufac-
turers especially for Swiss hospitals; and 3) medicines
imported from a foreign country.
Licensed medicines were further classified into three
classes: 1) medicines following the terms of the marketing
authorization; 2) medicines used in an off-label manner 
as they contained no information for paediatric use; and
3) medicines licensed for paediatric use, but off-label for:
a) age; b) indication and contra-indication; c) dose and fre-
quency of administration; or d) route of administration.
The primary reference source was the Swiss Drug
Compendium [12], edited by Documed Inc. and approved
by Swissmedic, the Swiss Agency for Therapeutic Prod-
ucts. Alternative sources of information included the pack-
age insert. All parts of the medicine’s monograph or pack-
age insert were screened for information regarding paedi-
atric use.
Data were collected on a database and summarised
using standard descriptive methods.
Patients and methods
Results
Sixty patients were included in our study (31
male, 29 female). Their median age was 1.6 years
(range 0.0–13.7). Eleven aged less than a month
(18.3%), 20 (33.3%) aged 1–23 months, 24
(40.0%) aged 2–11 years and 5 (8.3%) were ado-
lescents.
A total of 483 prescriptions were written for
the paediatric patients corresponding to 204 dif-
ferent medicines. The number of prescriptions per
patient ranged from 2 to 20, the median being 7.5.
The 10 most frequently administered drugs were
paracetamol (7%), morphine (5%), cholecalciferol
(4%), amoxicillin/clavulanic acid (3%), sodium
chloride (3%), mefenamic acid (3%), multivita-
mins (3%), heparin (3%), potassium chloride
(3%), and spironolactone (2%).
Of the 483 prescriptions, 369 (76%) were
licensed and 114 (24%) were unlicensed. Of the
369 licensed prescriptions, 247 (51%) followed 
the terms of the marketing authorisation and 122
(25%) were off-label. All patients received at least
one unlicensed or off-label medicine.
The incidence of unlicensed and off-label pre-
scriptions was higher in the paediatric intensive
care unit (58%) than in any other, especially the
neonatal (36%) and surgical wards (37%) (table 1).
The proportion of unlicensed and off-label
prescriptions was quite similar between the differ-
ent age groups (range 47–52%) (table 2). Infants
and toddlers (1–23 months) received more un-
licensed medicines (33%) than the other groups.
The most common reason of unlicensed pre-
Neonatology * Intensive Care * Intermediate Care * Medicine * Surgery * HEL ** Total
No of patients, n 10 10 10 10 10 10 60
No of prescriptions, 6.0 (3–12) 8.5 (3–20) 6.5 (4–10) 8.5 (6–13) 8.0 (5–12) 6.5 (2–12) 7.5 (2–20)
median (range)
No of prescriptions, 67 (100) 106 (100) 71 (100) 91 (100) 75 (100) 73 (100) 483 (100)
n (%)
Following the terms 43 (64) 44 (42) 36 (51) 41 (45) 47 (63) 36 (49) 247 (51)
of the marketing 
authorisation, n (%)
Total Unlicensed 24 (36) 62 (58) 35 (49) 50 (55) 28 (37) 37 (51) 236 (49)
and off-label, n (%)
Unlicensed, n (%) 14 (21) 28 (26) 16 (23) 15 (16) 17 (23) 24 (33) 114 (24)
Off-label, n (%) 10 (15) 34 (32) 19 (27) 35 (38) 11 (15) 13 (18) 122 (25)




in the six different
paediatric wards.
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scription was the administration of preparations
manufactured by the pharmacy (17% of the total
of prescriptions), followed by medicines sold espe-
cially to hospitals (4%) and foreign medicines
(2%). The most common category of off-label use
was the lack of specific paediatric information
(14%). The other off-label uses were related to age
(5%), dose and frequency of administration (5%),
indication & contra-indication (1%), and route of
administration (1%).
The ten most frequently prescribed unli-
censed and off-label drugs are shown in table 3.
0–28 days 1–23 months 2–11 years 12–18 years Total
No of patients, n 11 20 24 5 60
No of prescriptions, median (range) 6.0 (3–20) 8.0 (2–18) 7.5 (3–13) 9 (4–12) 7.5 (2–20)
No of prescriptions, n (%) 94 (100) 166 (100) 182 (100) 41 (100) 483 (100)
Following the terms of the marketing authorisation, n (%) 50 (53) 80 (48) 97 (53) 20 (49) 247 (51)
Total Unlicensed and off-label, n (%) 44 (47) 86 (52) 85 (47) 21 (51) 236 (49)
Unlicensed, n (%) 18 (19) 55 (33) 36 (20) 5 (12) 114 (24)
Pharmacy preparations, n (%) 9 (10) 42 (25) 27 (15) 4 (10) 82 (17)
Medicines prepared for Swiss hospitals*, n (%) 4 (4) 6 (4) 9 (5) 1 (2) 20 (4)
Foreign medicines, n (%) 5 (5) 7 (4) 0 (0) 0 (0) 12 (2)
Off-label, n (%) 26 (28) 31 (19) 49 (27) 16 (39) 122 (25)
No paediatric information, n (%) 13 (14) 14 (8) 26 (14) 13 (32) 66 (14)
Age, n (%) 6 (6) 10 (6) 6 (3) 0 (0) 22 (5)
Indication & contra-indication, n (%) 0 (0) 1 (1) 4 (2) 1 (2) 6 (1)
Dose & frequency, n (%) 6 (6) 3 (2) 11 (6) 2 (5) 22 (5)
Route of administration, n (%) 1 (1) 3 (2) 2 (1) 0 (0) 6 (1)





Medicines No (%) Licence category
Morphine injection 10 mg/ml 20 (4) Off-label (no paediatric information)
Sodium chloride injection 100 mg/ml 15 (3) Unlicensed (medicines prepared for Swiss hospitals)
Heparin injection 50 UI/ml 13 (3) Unlicensed (pharmacy preparation)
Spironolactone oral suspension 5 mg/ml 9 (2) Unlicensed (pharmacy preparation)
Hydrochlorothiazide oral suspension 5 mg/ml 8 (2) Unlicensed (pharmacy preparation)
Ondansetron injection 2 mg/ml 8 (2) Off-label for indication, or for dose & frequency, 
when administered differently from the label
Captopril oral capsules for paediatric use 5 (1) Unlicensed (pharmacy preparation)
Dopamine injection 25 mg/ml 5 (1) Off-label (no paediatric information)
Mefenamic acid suppositories 250 mg 5 (1) Unlicensed (pharmacy preparation)
Potassium chloride injection 7,45% 5 (1) Off-label for route of administration, when administered through 
an enteral tube
Table 3
The 10 drugs most





This study has shown that, as in other coun-
tries, the unlicensed and off-label use of medicines
in paediatric patients was frequent in our univer-
sity hospital where only about half of the pres-
criptions followed the terms of the marketing
authorisation.
After tragedies such as the sulfanilamide-re-
lated deaths in the 1930s and the birth defects as-
sociated with thalidomide in the 1960s, changes in
laws and regulations were introduced for the test-
ing of new drugs to ensure their effectiveness and
safety in humans [13]. The testing of medicines has
mainly benefited adults. With the exception of
some therapeutic classes, such as antibiotics and
vaccines, many medicines have not been tested in
children for ethical and economic reasons. This
problem is encountered in all countries, and
Switzerland is no exception to this situation. Con-
trary to the understanding of some physicians, it is
not illegal to prescribe unlicensed or off-label
medicines, but their use should be based on scien-
tific evidence, expert medical judgment, or the lit-
erature [14, 15]. Physicians must be aware of their
responsibilities and have sufficient knowledge or
experience to show that they are acting reasonably
and in the best interest of their patient [14, 15].
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In our study the drug use in the six wards dif-
fered. This is not astonishing as each of the wards
had different subspecialties and prescribing habits.
Several most commonly prescribed drugs were un-
licensed (oral morphine, sodium chloride additive,
diluted heparin, spironolactone suspension) or off-
label (morphine injection). Unlicensed or off-label
prescriptions were more frequent in the paediatric
intensive care unit, which had the highest number
of patients with complex therapy. In contrast, the
proportion was lowest in the neonatal ward. This
may imply that neonatologists are inherently con-
servative before administering drugs to premature
and term neonates.
Among the unlicensed medicines, an impor-
tant proportion consisted of in-house preparations
as a result of the lack of suitable commercialised
paediatric formulations. Some were batch prepa-
rations such as choral hydrate, caffeine citrate and
morphine solutions. Others were extemporaneous
preparations obtained by crushing the licensed
tablets or opening the capsules and using the con-
tents to prepare oral small strength capsules, solu-
tions or suspensions. This applied particularly to
cardiovascular drugs (captopril, furosemide, hy-
drochlorothiazide, and spironolactone). The pro-
duction of paediatric preparations in hospital phar-
macies is common to all European countries [16,
17]. The second category of unlicensed medicines
consisted of those specially produced for hospitals
by pharmaceutical companies. The third category
was foreign medicines imported from European
countries. For instance, oral digoxine solutions or
metronidazole suspensions were imported from
France, since no pharmaceutical company cur-
rently markets them in our country. The import of
medicines may resolve the problem of extempora-
neous preparations. However, three concerns
occur with foreign medicines: 1) the different lan-
guage of the package insert; 2) their availability in
a public pharmacy once the patient is discharged;
and 3) their reimbursement by the health insur-
ance company.
Many licensed medicines were used in an off-
label manner because information regarding pae-
diatric use was not available. Most, such as mor-
phine and dopamine, have been prescribed for a
long time worldwide. Consequently, other sources
of information from the USA, United Kingdom
and Australia are used in our hospital by physicians
for paediatric patients. These references some-
times recommend varying dose ranges and pose a
dilemma for paediatricians when deciding on the
proper treatment. Regarding the other medicines
used in an off-label manner, age limitations or
doses decided by the manufacturers were in con-
trast with the clinical reality. Thus, metered-dose
inhaler of salbutamol contained dose information
for children over 4 years, but there is a large expe-
rience of use in infants and toddlers. In another ex-
ample, gentamicin doses in neonates were adapted
from results of therapeutic drug monitoring of
plasma levels and, in such a case, off-label use is an
alternative to the doses described in the label [18].
The frequency of unlicensed and off-label
drug prescriptions reported in the literature varies
according to methods and clinical settings [3–10].
For example, Conroy et al. [6] have found 7% un-
licensed and 39% off-label medicines in the pae-
diatric medical wards of five European hospitals,
and ‘t Jong et al. [8] have identified 28% unlicensed
and 44% off-label medicines in a paediatric ward
of a general hospital in the Netherlands. Finally,
Lampert et al. [10] have found 10% unlicensed and
46% off-label prescriptions in the neonatal and
paediatric intensive care units of the Basel Univer-
sity Hospital (Switzerland). 
Our results should be interpreted in the light
of the study’s limitations. This being a pilot study,
60 patients were included and were representative
of the commonest categories of hospitalised pae-
diatric patients during the review period. More-
over, the 204 various medicines represented 75%
of those most commonly ordered from the phar-
macy by the six wards during the study period. We
also chose to consider only 24 hours of hospitali-
sation in order to allow comparisons between the
paediatric wards and between the age categories.
Finally, we did not analyse the proportion of com-
mercial medicines handled and modified by nurses
before intravenous administration. We considered
that many intravenous medicines were marketed
for adults and that their dilution was a common
practice. We therefore recorded only their licence
category. It is important to add that, even though
dilution of intravenous formulations may be com-
monplace in a paediatric setting, it is not without
its risks to paediatric patients [19].
Being aware of the above problems and paral-
lel to the European Agency for the Evaluation of
Medicinal Products [20], the Swiss Agency for
Therapeutic Products has decided on measures to
improve the situation for paediatric patients [21].
Firstly, during the license revision of each medi-
cine, information regarding paediatric use in the
leaflet will be checked and a complement re-
quested if necessary. Secondly, manufacturers who
voluntary conduct a new drug development for
children will obtain an additional 5-year data pro-
tection. It will be interesting to observe the conse-
quences of these two decisions in the coming years
in university hospitals and in other settings (non
teaching hospitals, ambulatory practice). 
In conclusion, the use of unlicensed or off-
label medicines to treat children was found to be
common in paediatric inpatients in a Swiss univer-
sity hospital. Cooperation between the pharma-
ceutical industry, regulatory authorities, clinical
researchers, healthcare professionals and parents 
is required in order to ensure that children do not
remain “therapeutic orphans”.
The authors thank Prof. Bernard Testa for his criti-
cal reading and correction of the manuscript.
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